A total of 95 Equity Offering deals (pending and completed) were announced in the Pharmaceuticals of the Asia-Pacific region, in the last twelve months resulting in a total deal value of over $18,899.8 million. In the LTM period, December 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $5,471.7 million, resulting in an average deal value of $420.9 million during that month. On the other hand, the month of November 2021 was the most prolific in terms of deal volume, recording a total of 14 deals, resulting in an average deal value of $326.0 million during that month.
Of the 95 deals, the deal secured between Sino Biopharmaceutical Ltd; Yifan Pharmaceutical Co Ltd and Yiyi Biopharmaceutical (Beijing) Co., Ltd., was the largest Equity Offering deal in the Asia-Pacific Pharmaceuticals sector, which was valued at $70.0 million and was completed on June 2, 2022. The second-largest deal was between Innovent Biologics Inc and Ascentage Pharma Group International, while the third-largest deal was between Asset One Asset Management Co Ltd; Company K Partners Limited; IBK Securities Co. Ltd.; Meritz Securities Co Ltd and KoBioLabs Inc. The Innovent Biologics Inc-Ascentage Pharma Group International deal and the Asset One Asset Management Co Ltd; Company K Partners Limited; IBK Securities Co. Ltd.; Meritz Securities Co Ltd-KoBioLabs Inc deal were valued at $50.0 million and $28.5 million, respectively. The fourth-largest deal was between Changsha Xingchen Kangrui Venture Capital Partnership Enterprise; Hunan Fangsheng Pharmaceutical Co Ltd-Hunan Fangsheng Ruixin Pharmaceutical Co Ltd valued at $25.1 million, whereas the deal between Zhuhai Zhifan Enterprise Management Consulting Center-Guangzhou Mingkang Biological Engineering Co Ltd valued at $24.2 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $197.8 million and accounted for nearly 1.05% of the total deals (by value) announced during the last twelve months. The Asia-Pacific region accounted for 28.82% of the total Equity Offering deals done globally, and accounted for 0.34% of the total deal size on a global scale.
United States of America
China
United States of America
United States of America
United States of America
United States of America
United States of America
United Kingdom
Switzerland
France
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer